Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Investor Presentation (March 2024)
32 slides from Balaxi Pharmaceuticals's investor presentation, March 2024
Slide 1: Balaxi Pharmaceuticals Limited Company Overview
Balaxi Pharmaceuticals Limited Company Overview
Slide 2: Disclaimer and Table of Contents
Balaxi Disclaimer and Table of Contents Corporate Presentation - March 2024. Disclaimer Table of Contents Certain statements in this document may be About Balaxi 2-10 forward-looking statements. Such forward- looking statements are subject to certain risks Our Strategies 11-13 and uncertainties like
Slide 3: About Balaxi
Balaxi About Balaxi Corporate Presentation - March 2024. Balaxi Balaxi Pharmaceuticals Limited, a global pharmaceutical leader in ROW markets. Specialization: Focus on IPR based pharmaceutical products Operational Regions: Currently active in Latin America, Caribbean Islands and Africa Product Portf
Slide 4: Focus on Frontier Markets and Diverse Product Portfolio
Balaxi Corporate Presentation - March 2024. Focus on Frontier Diverse Product Markets Portfolio Global pharmaceutical Diverse product leader with a focus on portfolio spanning various frontier markets in finished dosage forms, from high Latin America, The volume product segments such Caribbean and A
Slide 5: Products & Therapeutic Areas
Balaxi Products & Therapeutic Areas Corporate Presentation - March 2024. Antibiotic Diuretic 84 5 Analgesic Hormone 65 4 Medical Device Anti-Emetic 32 4 Vitamin Bronchodilator 26 3 Anti-Malaria Local Anesthetic 16 3 Erectile Dysfunction Anemia 8 2 Hypertension Anti-Diarrhea 10 2 Anti-Asthma Antihist
Slide 6: Major Dosage Forms
Balaxi Major Dosage Forms Corporate Presentation - March 2024. Injectables Tablets Liquids Capsules IVs 5
Slide 7: Management Message
Balaxi Management Message Corporate Presentation - March 2024. Balaxi Pharmaceuticals, an IPR-driven and asset-light pharmaceutical company is presently strategically focused in frontier markets in Latin America, The Caribbean, and Africa. In the coming years, we intend to expand in markets in South
Slide 8: Key Milestones
Balaxi Key Milestones Corporate Presentation - March 2024. Started business supplying white labelled products to customers Created front-end Diversified supply in Africa (Products presence by setting up chain by sourcing were sourced from WHO the first pharma pharma products from GMP certified plant
Slide 9: Corporate Structure
Balaxi Corporate Structure Corporate Presentation - March 2024. Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS*) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Central African Dominica Gua
Slide 10: Shareholding Pattern
Balaxi Shareholding Pattern Corporate Presentation - March 2024. Public 34 66 Promoter 9
Slide 11: Transformative Stride
Balaxi Transformative Stride Corporate Presentation - March 2024. Backward Integration The company is undertaking a backward integration, transitioning from complete outsourcing to developing internal manufacturing capabilities near Hyderabad. Asset-light Advantages Retaining asset-light advantages
Slide 12: Balaxi's Strategic Foundation
Balaxi Balaxi’s Strategic Foundation Corporate Presentation - March 2024. Our Mission Our vision is to be amongst the top pharmaceutical players in multiple global frontier markets, giving us scale, market homogeneity, healthy margins, and quality growth where value and volume are both established i
Slide 13: Strategic Horizons: Balaxi Pharma's Vision for Global Leadership
Balaxi Strategic Horizons Corporate Presentation - March 2024. Balaxi Pharma's Vision for Global Leadership Balaxi Pharma has meticulously outlined SHORT TERM a three-tiered strategic vision to navigate its evolution and ascendancy in the pharmaceutical landscape. Collectively, these strategic horiz
Slide 14: Strategic Horizon
Balaxi Strategic Horizon Corporate Presentation - March 2024. Strategy Description Strategic Horizon Market Entry and Focus on immediate market entry into select new regions with high growth potential. Near Term Expansion Leverage existing product portfolios to establish a foothold in these markets.
Slide 15: Four Pillars of our Business Model
Balaxi Four Pillars of our Business Model Corporate Presentation - March 2024. Pillar 1 Pillar 2 Customer Value Resources Proposition Pillar 4 Pillar 3 Profit Formula Processes 14
Slide 16: Business Model – Pillar 1: Value Created
Balaxi Business Model – Pillar 1: Value Created Corporate Presentation - March 2024. Value Created Quality Assurance: Procurement from WHO GMP certified manufacturers. Access to Essential Medicines: Availability in frontier markets. Addresses healthcare needs in underserved regions. IPR Protection:
Slide 17: Business Model – Pillar 2: Our Resources
Balaxi Business Model – Pillar 2: Our Resources Corporate Presentation - March 2024. Resources Extensive Product Portfolio: 960 products across 30+ therapeutic areas and diverse finished dosage forms. Strong Distribution Networks: Particularly well-established in frontier markets. Experienced Regula
Slide 18: Business Model – Pillar 3: Our Processes
Balaxi Business Model – Pillar 3: Our Processes Corporate Presentation - March 2024. Processes Proprietary Market Research: Conducts thorough market research to assess demands. Utilises proprietary insights to stay ahead of market trends and dynamics. Product Registration: Expertise in filing techni
Slide 19: Business Model – Pillar 4: Profit Formula
Balaxi Business Model – Pillar 4: Profit Formula Corporate Presentation - March 2024. Revenue and Profit Formula Revenue Visibility Growth: Balaxi's revenue and profit formula emphasises increased revenue visibility over the years, which is attributed to the strategic expansion of markets. Balaxi ai
Slide 20: Global Footprints
Balaxi Global Footprints Corporate Presentation - March 2024. Portugal Dominican China Republic Guatemala India Honduras El Salvador Nicaragua Central African Republic Angola Chile Existing Market Targeted Expansion Product Sourcing Regions 19
Slide 21: Market Overview - Pharma Exports from India
Balaxi Market Overview - Pharma Exports from India Corporate Presentation - March 2024. India's Country-wise share of drugs, pharmaceutical and fine-chemicals exports (2022-23) The Indian pharmaceutical industry aspires to 29.72% reach the milestones of US$130 billion by 2030 and US$450 billion by B
Slide 22: Market Overview - Latin America
Balaxi Market Overview - Latin America Corporate Presentation - March 2024. Latin America Exports during The total pharma is the emerging April-December market in the region market for Indian period of FY24 is estimated to be pharmaceuticals were at $1.348 around $59. 77 with a share of billion with
Slide 23: Key Existing Markets
Balaxi Key Existing Markets Corporate Presentation - March 2024. Guatemala Dominican Republic Honduras Guatemala's pharmaceutical market The pharmaceutical market in the Honduras, the 4th largest pharmaceutical is poised for revenue growth, Dominican Republic sees growing market in Central America,
Slide 24: Key Existing Markets
Balaxi Key Existing Markets Corporate Presentation - March 2024. EL Salvador Angola Central African Republic El Salvador's pharmaceutical market Angola's pharmaceutical market is The Central African Republic's anticipates exponential growth, dynamic, with emerging opportunities pharmaceutical market
Slide 25: Potential in New Markets
Balaxi Potential in New Markets Corporate Presentation - March 2024. Nicaragua Chile Ecuador The pharmaceuticals market in Chile is projected to experience a The revenue in Ecuador’s Nicaragua is projected to significant rise in its total Consumer Pharmaceuticals market is forecasted to grow by 3.86
Slide 26: Market Expansion Strategy for Balaxi
Balaxi Market Expansion Strategy for Balaxi Corporate Presentation - March 2024. Leveraging Intellectual Strategic Navigating Optimising Targeting Property Collaboration Regulatory Supply Chain Growth Regions: Advantage: and Licensing: Landscapes: Dynamics: For successful Focus on Tapping into the N
Slide 27: Core Strengths of Balaxi
Balaxi Core Strengths of Balaxi Corporate Presentation - March 2024. 20 Years of Domain 38 Warehouses 960 Product registrations Experience across six countries across eight countries Balaxi excels in market research, product Established in the existing markets of registration, and regulatory knowled
Slide 28: Our Value Chain
Balaxi Our Value Chain Corporate Presentation - March 2024. Value Creation Market Analysis Product Identification and Outsourcing Our emphasis is on making Through rigorous market analysis, essential medicines accessible we strategically build portfolios We identify products and in challenging front
Slide 29: Board of Directors
Balaxi Board of Directors Corporate Presentation - March 2024. Mr. Ashish Maheshwari Mrs. Minoshi Maheshwari Mr. Kunal Bhakta Mr. Gandhi Gamji Mr. Mangina Srinivas Rao Chairman & Non-Executive Director Independent Director Independent Director Independent Director Managing Director Ashish Maheshwari
Slide 30: Senior Management
Balaxi Senior Management Corporate Presentation - March 2024. Mr. Ashish Maheshwari Mr. Amol Mantri Managing Director Chief Financial Officer Mr. Pranav Maheshwari Ms. Paridhi Maheshwari Senior Vice President – Head – Alternate Channels Business Development 29
Slide 31: Environmental, Social, and Governance
Balaxi Environmental, Social, and Governance Corporate Presentation - March 2024. Balaxi Pharma, an affordable pharmaceutical company, excels in Environmental, Social, and Governance (ESG) aspects. With an asset- light model, it minimizes environmental impact, while a robust regulatory mechanism ens
Slide 32: Thank You
Balaxi Thank You
Balaxi Pharmaceuticals — Investor Presentation (March 2024) on 6ix